Press Releases
BERKELEY, CA and RICHMOND, CA – February 19, 2020 – Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies, Inc., a biotechnology CRO/CDMO specializing in antibody engineering and CAR-T development, today announced a sale and assignment agreement under which Caribou gains access to a ProMab humanized single-chain variable fragment (scFv) targeting the B Cell Maturation Antigen (BCMA) for use in allogeneic engineered cell therapies.
BERKELEY, CA – September 26, 2019 – On September 19, 2019, a three-member JAMS panel issued an Interim Award in the arbitration between Intellia Therapeutics, Inc. (Intellia) and Caribou Biosciences, Inc. (Caribou). On October 17, 2018, Intellia initiated an arbitration proceeding with JAMS asserting that Caribou was violating the terms and conditions of the license agreement between Caribou and Intellia as it related to certain disputed technology in a defined field of human therapeutics.
BERKELEY, CA – February 12, 2019 – Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced today that it has expanded its Scientific Advisory Board (SAB) with the appointment of six new members: Emily Balskus, PhD; Ami Bhatt, MD, PhD; Dean Lee, MD, PhD; Jeffrey Rathmell, PhD; Noopur Raje, MD; and Cameron Turtle, MBBS, PhD. The newly appointed members will work with current SAB members and Caribou co-founders Jennifer Doudna, PhD and Martin Jinek, PhD.
BERKELEY, CA – December 12, 2018 – Caribou Biosciences, Inc., a leading genome editing company, announced today that it has appointed Natalie Sacks, MD to its Board of Directors. Dr. Sacks is an accomplished industry leader and oncology expert who has played a key role in the development and approval of several oncology therapeutics.